BACKGROUND: Primary Ciliary Dyskinesia (PCD) is an orphan disease characterized by recurrent respiratory infections and an increased prevalence of situs inversus and male infertility. Low nasal Nitric Oxide (nNO) is used as a new test to diagnose PCD. The test sensitivity is good, but specificity has not been studied widely. Therefore, we evaluated the diagnostic accuracy of low nNO to diagnose PCD in a large cohort, including healthy patients and different disease controls. MATERIALS AND METHODS: Nasal nitric oxide was measured during plateau exhalation against resistance (nNOplat) and during tidal breathing (nNOtid). Moreover, we measured fractional exhaled NO (FENO). We included 226 patients: 38 with PCD, 49 healthy controls, and 139 disease controls (cystic fibrosis, humoral immunodeficiency, and asthma). RESULTS: The nNOplat cut-off value of 300 ppb provided the best sensitivity (89·5%) and specificity (87·3%) to detect PCD. There was overlap between PCD and disease controls: 16·5% of disease controls had a false-positive result. nNOtid correlated with nNOplat (r=0·912), but values differed (P=0·0001). The nNOtid cut-off of 200 ppb had a sensitivity of 89·5% and a specificity of 80·6% to detect PCD. The FENO cut-off of 10 ppb had an acceptable sensitivity (89·5%), but a low specificity (58·3%). Positive and negative likelihood ratios were suboptimal for all tests. CONCLUSIONS: nNOplat, nNOtid and FENO measurements overlap between PCD and disease controls. Sensitivity is comparable for the three tests. Applying composite scores slightly improves diagnostic accuracy. Given the less than 90% test sensitivity, PCD should be considered in patients with intermediate results.
BACKGROUND:Primary Ciliary Dyskinesia (PCD) is an orphan disease characterized by recurrent respiratory infections and an increased prevalence of situs inversus and male infertility. Low nasal Nitric Oxide (nNO) is used as a new test to diagnose PCD. The test sensitivity is good, but specificity has not been studied widely. Therefore, we evaluated the diagnostic accuracy of low nNO to diagnose PCD in a large cohort, including healthy patients and different disease controls. MATERIALS AND METHODS: Nasal nitric oxide was measured during plateau exhalation against resistance (nNOplat) and during tidal breathing (nNOtid). Moreover, we measured fractional exhaled NO (FENO). We included 226 patients: 38 with PCD, 49 healthy controls, and 139 disease controls (cystic fibrosis, humoral immunodeficiency, and asthma). RESULTS: The nNOplat cut-off value of 300 ppb provided the best sensitivity (89·5%) and specificity (87·3%) to detect PCD. There was overlap between PCD and disease controls: 16·5% of disease controls had a false-positive result. nNOtid correlated with nNOplat (r=0·912), but values differed (P=0·0001). The nNOtid cut-off of 200 ppb had a sensitivity of 89·5% and a specificity of 80·6% to detect PCD. The FENO cut-off of 10 ppb had an acceptable sensitivity (89·5%), but a low specificity (58·3%). Positive and negative likelihood ratios were suboptimal for all tests. CONCLUSIONS: nNOplat, nNOtid and FENO measurements overlap between PCD and disease controls. Sensitivity is comparable for the three tests. Applying composite scores slightly improves diagnostic accuracy. Given the less than 90% test sensitivity, PCD should be considered in patients with intermediate results.
Authors: Majid Afshar; Jill A Poole; Guichan Cao; Ramon Durazo; Richard C Cooper; Elizabeth J Kovacs; Joseph H Sisson Journal: Chest Date: 2016-02-19 Impact factor: 9.410
Authors: Adam J Shapiro; Sharon D Dell; Benjamin Gaston; Michael O'Connor; Nadzeya Marozkina; Michele Manion; Milan J Hazucha; Margaret W Leigh Journal: Ann Am Thorac Soc Date: 2020-02
Authors: Jacelyn E Peabody; Ren-Jay Shei; Brent M Bermingham; Scott E Phillips; Brett Turner; Steven M Rowe; George M Solomon Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-03-01 Impact factor: 5.464
Authors: Adam J Shapiro; Maureen Josephson; Margaret Rosenfeld; Ozge Yilmaz; Stephanie D Davis; Deepika Polineni; Elena Guadagno; Margaret W Leigh; Valery Lavergne Journal: Ann Am Thorac Soc Date: 2017-07
Authors: Margaret W Leigh; Amjad Horani; BreAnna Kinghorn; Michael G O'Connor; Maimoona A Zariwala; Michael R Knowles Journal: Transl Sci Rare Dis Date: 2019-07-04
Authors: Panayiotis Kouis; Panayiotis K Yiallouros; Nicos Middleton; John S Evans; Kyriacos Kyriacou; Stefania I Papatheodorou Journal: Pediatr Res Date: 2016-12-09 Impact factor: 3.756
Authors: Zofia N Zysman-Colman; Kimberley R Kaspy; Reza Alizadehfar; Keith R NyKamp; Maimoona A Zariwala; Michael R Knowles; Donald C Vinh; Adam J Shapiro Journal: J Clin Immunol Date: 2019-03-26 Impact factor: 8.317
Authors: Adam J Shapiro; Stephanie D Davis; Deepika Polineni; Michele Manion; Margaret Rosenfeld; Sharon D Dell; Mark A Chilvers; Thomas W Ferkol; Maimoona A Zariwala; Scott D Sagel; Maureen Josephson; Lucy Morgan; Ozge Yilmaz; Kenneth N Olivier; Carlos Milla; Jessica E Pittman; M Leigh Anne Daniels; Marcus Herbert Jones; Ibrahim A Janahi; Stephanie M Ware; Sam J Daniel; Matthew L Cooper; Lawrence M Nogee; Billy Anton; Tori Eastvold; Lynn Ehrne; Elena Guadagno; Michael R Knowles; Margaret W Leigh; Valery Lavergne Journal: Am J Respir Crit Care Med Date: 2018-06-15 Impact factor: 21.405